NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $515,000 | +56.5% | 28,689 | +49.4% | 0.01% | +40.0% |
| Q2 2021 | $329,000 | -15.4% | 19,198 | -1.2% | 0.01% | -28.6% |
| Q1 2021 | $389,000 | +15.1% | 19,429 | -2.4% | 0.01% | +16.7% |
| Q4 2020 | $338,000 | -52.7% | 19,904 | -53.8% | 0.01% | -60.0% |
| Q3 2020 | $715,000 | -44.5% | 43,079 | -27.9% | 0.02% | -74.1% |
| Q4 2019 | $1,289,000 | +119.2% | 59,737 | +85.1% | 0.06% | +346.2% |
| Q3 2019 | $588,000 | -25.3% | 32,268 | +46.0% | 0.01% | -31.6% |
| Q2 2019 | $787,000 | +51.1% | 22,107 | +42.7% | 0.02% | +35.7% |
| Q1 2019 | $521,000 | -41.1% | 15,494 | -42.4% | 0.01% | -54.8% |
| Q4 2018 | $884,000 | -37.9% | 26,891 | +15.2% | 0.03% | -42.6% |
| Q3 2018 | $1,424,000 | +294.5% | 23,352 | +215.9% | 0.05% | +237.5% |
| Q2 2018 | $361,000 | -44.8% | 7,393 | +20.2% | 0.02% | -55.6% |
| Q1 2018 | $654,000 | – | 6,153 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |